INVOKANA: payments to doctors
Payments that named INVOKANA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $10.4M
- Providers
- 40,430
- Transactions
- 170,093
- Average per transaction
- $61
The per-transaction average — $61 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 40,430 providers the average total is $256, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Johnson & Johnson | $9,940,634 | 95.9% |
| Janssen Scientific Affairs, LLC | $283,460 | 2.7% |
| Janssen Research & Development, LLC | $136,329 | 1.3% |
| Janssen Global Services, LLC | $3,623 | 0.0% |